VIVES is a multi-sector fund that invests in projects with a positive societal impact
Founded in 2020, Brightflow is a medical device startup company based in Paris, France. The team’s vision is to bring to market the first long-term mechanical assist device to support RV failure...
Emolytics is a spin-off company of UCLouvain (Belgium) which is closely supported by the Louvain Technology Transfer Office. The technology originated in the University's research center in 2009 as a...
The Akkermansia company is the first co-spin-off resulting from joint research conducted at two European universities, the Catholic University of Louvain (Belgium) and the University of Wageningen...
David Frenay, CEO Emolytics :
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Denis Périquet, CEO Tessares :
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Georges Caron, past CEO Keemotion :
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with...
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease